GlassScriptPhysician profile
Joseph A Lovato
NPI 1558332247
$15,464.22
in general payments reported to CMS, 2019-2025
58 companies · $2,665 in 2025
The $2,665 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,956 · 2020: $1,632 · 2021: $2,474 · 2022: $1,971 · 2023: $2,561 · 2024: $2,206 · 2025: $2,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,431.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,882.41 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,940.64 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,151.02 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,075.31 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $1,031.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $757.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $754.38 | 2019-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $715.64 | 2019-2025 | Spravato, Xarelto |
| Pfizer INC. | $569.37 | 2019-2025 | |
| Abbott Laboratories | $506.07 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $383.64 | 2019-2025 | |
| Astellas Pharma US INC | $319.39 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $278.51 | 2021-2025 | |
| Allergan, INC. | $248.13 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $219.67 | 2019-2024 | Austedo Xr, Austedo |
Show all 57 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Lovato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.